CalciMedica, Inc. Reports Nasdaq Listing Update; 1-for-5 Reverse Split

What Happened

• CalciMedica announced that Nasdaq has closed a March 13, 2026 notice that the company was not meeting the market value of listed securities (MVLS) $35M requirement because Nasdaq determined CalciMedica now meets the alternative minimum stockholders’ equity test. This determination was based on the company’s Form 10-Q for the quarter ended June 30, 2026, which reported stockholders’ equity of $5,513,000.
• Separately, the company remains out of compliance with Nasdaq’s $1.00 minimum bid price rule (notice dated March 16, 2026) and has until September 14, 2026 to regain compliance. CalciMedica implemented a one-for-five reverse stock split of its common stock effective August 28, 2026 at 5:00 p.m. ET. The company notes there is no assurance it will regain or maintain compliance.

Key Details

• Nasdaq MVLS notice date: March 13, 2026; Nasdaq closed the matter on August 31, 2026 after equity test compliance.
• Reported stockholders’ equity (Q2 2026 Form 10-Q): $5,513,000.
• Minimum bid price noncompliance notice date: March 16, 2026; cure deadline: September 14, 2026.
• Reverse stock split: one-for-five implemented August 28, 2026 at 5:00 p.m. ET.

Why It Matters

• For investors, Nasdaq closing the MVLS notice removes one near-term listing risk (market-cap test) because the company qualified under the alternate equity standard, but the listing remains contingent on meeting other rules.
• The outstanding minimum bid-price deficiency is still material: if the company does not restore a sustained $1.00+ share price by September 14, 2026, it could face additional Nasdaq actions, including potential delisting procedures.
• The one-for-five reverse split reduces share count and typically raises the per-share price, which may help meet the minimum bid price requirement, but the company warns there is no guarantee of regaining compliance.